Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Non Operating Income (2019 - 2025)

Black Diamond Therapeutics' Non Operating Income history spans 5 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 8.91% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $9.8 million, up 21.17%, while the annual FY2025 figure was $9.8 million, 8.13% up from the prior year.
  • Non Operating Income reached $2.5 million in Q4 2025 per BDTX's latest filing, up from $2.5 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.9 million in Q2 2025 to a low of -$740000.0 in Q1 2021.
  • Average Non Operating Income over 3 years is $1.6 million, with a median of $2.0 million recorded in 2024.
  • The largest YoY upside for Non Operating Income was 186.05% in 2021 against a maximum downside of 7300.0% in 2021.
  • A 3-year view of Non Operating Income shows it stood at -$489000.0 in 2021, then skyrocketed by 568.3% to $2.3 million in 2024, then increased by 8.91% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Non Operating Income are $2.5 million (Q4 2025), $2.5 million (Q3 2025), and $2.9 million (Q2 2025).